Blood
Articles in this Issue
Preliminary data on epcoritamab and glofitamab as bridging therapy prior to CAR T-cell treatment in Relapsed/Refractory large B cell lymphoma
Abstract Introduction: CAR T-cell therapies are currently approved as a second-line (2L) treatment for early relapsed or...
Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms
Abstract Introduction Detecting genetic abnormalities is mandatory during diagnostic workup and for potential individualization of therapy s...
Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter
Abstract Introduction Bridging therapy is frequently required during the treatment course of CD19-directed chimeric anti...
Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival
Abstract Introduction: Although CD19-directed chimeric antigen receptor T-cell therapies (CAR-T) have improved the prognosis for patients (pt...
Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML
Abstract Background：According to the 2022 WHO classification, acute myeloid leukemia (AML) with CEBPA mutations is considered a unique subt...
The use of eculizumab and tocilizumab in the treatment of hyperhemolysis syndrome, a literature review
Abstract Introduction: Hyperhemolysis Syndrome (HHS) is a rare but severe complication of red blood cell transfusion, ch...
Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy
Abstract Background Olverembatinib, a third-generation BCR::ABL1tyrosine kinase inhibitor (TKI), has demonstrated promising efficacy in resi...
The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).
Abstract Background: Bronchiolitis obliterans syndrome (BOS) is the most common late-onset pulmonary complication following allogeneic hemat...
Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy
Abstract Introduction: Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL in the US and after ≥2 prior...
GMP-manufactured allogeneic human t lymphoid progenitors (HTLP) promote early and sustained T-cell recovery after CD34+-selected haploidentical HSCT in SCID patients : Final results of the htlp-SCID study
Abstract Introduction : Alternative donor Hematopoietic Stem Cell Transplantation (HSCT) is often associated with delayed immune reconstitut...
Diagnosis, management, and outcomes of tumor-associated erythrocytosis: A systematic review
Abstract Background: Secondary erythrocytosis (SE) refers to elevated hemoglobin (>160 g/L in women or >165 g/L in men) not du...
Concizumab plasma concentration measurements for personalized dose adjustment in patients with Hemophilia A/B with and without inhibitors: Data from the Phase 3 explorer7 and explorer8 studies
Abstract Background Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for patients with hemophilia A...
Ferritin reference ranges and improving diagnosis of iron deficiency without anemia
Abstract Background: Iron deficiency without anemia (IDWA) is increasingly recognized as a distinct cause of morbidity separate from iron de...
Nonclinical evaluation of APL-4098, a novel GCN2 kinase inhibitor, reveals potent anti-leukemic effects through mitochondrial stress induction and synergy with venetoclax, targeting AML blasts and LSCs
Abstract Background: Despite recent progress in acute myeloid leukemia (AML) therapy, long-term outcomes remain dismal, primarily due to the...
Differences in outcomes with intensive chemotherapy in AML patients according to mutational status – recent real-world results
Abstract Background: Most studies have found that European LeukemiaNet (ELN) Intermediate risk AML patients treated with intensive chemothera...
Characteristics and outcomes of non-transplanted newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) with once-weekly bortezomib dosing
Abstract Background: The phase 3 CEPHEUS trial showed that the daratumumab-based quadruplet regimen comprised of daratumumab, bortezomib, le...
Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies
Abstract Background Patients with T-cell lymphomas and other mature T-cell malignancies are at increased risk of developing subsequent B-cel...
Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study
Abstract Background Polatuzumab vedotin (Pola), an anti-CD79b monoclonal antibody-drug conjugate, has been approved for first-line treatment...
Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).
Abstract Introduction: Therapeutic options are limited for previously treated, transfusion-dependent (TD) LR-MDS patients (pts).R835 is a se...
Clonal T-large granular lymphocytes (LGL) in chronic relapsing-remitting and refractory immune thrombocytopenia
Abstract Background Adult chronic immune thrombocytopenia (ITP)is a disease associated with a history of recurrent relapses and subsequent r...
Patients with thalassemia have weaker bones relative to body size compared with healthy controls
Abstract Background: Despite optimal transfusion and chelation regimens, up to 60% of adults with thalassemia (Thal) have low bone mass and...
Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study
Abstract Background: Follicular lymphoma (FL) is a generally indolent disease, yet clinical outcomes vary, with a persistent risk of histolog...
Long term remission and survival in patients with relapsed or refractory non-Hodgkin lymphoma after treatment of brl-201, a CRISPR-based non-viral PD-1 locus specifically integrated anti-CD19 CAR-T cells: 4-year follow-up of a first-in-human phase I study
Abstract BACKGROUND: Currently approved CAR-T products were all derived from viral vector transfection, which increases a potential tumorige...
Antithrombin deficiency, venous thromboembolism risk, and peripartum antithrombin supplementation: A real-world analysis of delivery encounters from 2015–2024
Abstract Background: Pregnant individuals with antithrombin (AT) deficiency have an increased risk for thromboembolic complications during pr...
Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting
Abstract Background: Older adults with AML face unique treatment challenges due to age-related comorbidities, reduced tolerance to therapy,...